William A. Sarraille

Sep 18, 2024 | linkedin.com | William A. Sarraille

William Sarraille’s Post Nationally Recognized Expert in Health Care and Life Sciences, Educator, Regulatory Consultant, Patient Access Advocate, Independent Director, and Retired Sidley Austin Partner 4h Edited Boy, Have I Got a LOT to Say about ESI’s FTC Lawsuit Where to start?

Jul 17, 2023 | lexology.com | Meenakshi Datta |Stephanie P. Hales |Elizabeth Hardcastle |Donielle McCutcheon |William A. Sarraille |Catherine Y. Starks | +1 more

In the past two weeks, the Centers for Medicare & Medicaid Services (CMS) unveiled important details regarding implementation of the Medicare Drug Price Negotiation Program (Negotiation Program) under the Inflation Reduction Act (IRA).

Jul 11, 2023 | lexology.com | Stephanie P. Hales |Meenakshi Datta |William A. Sarraille |Trevor L. Wear |Taylor Andelman

On June 22, 2023, the Centers for Medicare and Medicaid Services (CMS) released a Notice With Comment Period outlining a proposed Transitional Coverage for Emerging Technologies (TCET) pathway under Medicare that would be available for certain devices that the Food and Drug Administration (FDA) has designated as Breakthrough Devices. Comments are due by August 28, 2023.

May 31, 2023 | lexology.com | Catherine Y. Starks |Meenakshi Datta |Elizabeth Hardcastle |Donielle McCutcheon |William A. Sarraille |Trevor L. Wear | +2 more

On May 23, 2023, the U.S. Centers for Medicare & Medicaid Services (CMS) issued a proposed rule that addresses a variety of important drug pricing matters under the Medicaid Drug Rebate Program (MDRP).

Feb 23, 2023 | lexology.com | Elizabeth Hardcastle |Meenakshi Datta |Stephanie P. Hales |Donielle McCutcheon |William A. Sarraille |Catherine Y. Starks | +2 more

On February 14, the U.S. Department of Health and Human Services (HHS)  that the HHS Secretary had selected three new payment and service delivery models for testing by the Center for Medicare & Medicaid Innovation (CMS Innovation Center). HHS has directed the CMS Innovation Center to test whether these new models result in lower prescription drug costs, promote accessibility to therapies, and/or improve quality of care.